In this article, we explore regulatory developments in stem cell medicine in seven
jurisdictions: Japan, China, India, Argentina, Brazil, the USA and the EU. We will show that …

Commentary Rosemann & Sleeboom-Faulkner online at the Chinese Medicine Registry and
Management System. The NHFPC and CFDAs will jointly review the projects at a provincial …

Aim: To provide a comprehensive analysis of clinical trials (CTs) listed in worldwide
registries involving new applications for stem cell-based treatments and account for the role …

This chapter explores regulatory developments for nonhematopoietic stem cell therapies in
Japan, China, India, Argentina, Brazil, the USA, and the European Union. The chapter …

The article examines the role and challenges of scientific self-governance and
standardization in inter-continental clinical research partnerships in stem cell medicine. The …

The unproven stem cell intervention (SCI) industry is a global health problem. Despite efforts
of some nations, the industry continues to flourish. In this paper, we call for a global …

Harmonized regulation of research with human stem cells in Europe has shaped innovation
in regenerative medicine. Findings from a Phase III academic clinical trial of an autologous …

In the context of regenerative medicine and cellular therapies, the treatment under study
often targets a less common disease or condition for which recruitment of a large number of …

The phrase “bench-to-bedside” is commonly used to describe the translation of basic
discoveries such as those on stem cells to the clinic for therapeutic use in human patients …

Regenerative medicine has great potential. The pace of scientific advance is exciting and
the medical opportunities for regeneration and repair may be transformative. However …